Cohen Investment Advisors LLC Has $689,000 Holdings in Astrazeneca Plc $AZN

Cohen Investment Advisors LLC reduced its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 50.4% during the 1st quarter, Holdings Channel.com reports. The fund owned 3,557 shares of the company’s stock after selling 3,618 shares during the period. Cohen Investment Advisors LLC’s holdings in Astrazeneca were worth $689,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Kiley Juergens Wealth Management LLC bought a new position in shares of Astrazeneca during the 1st quarter worth approximately $394,000. PUREfi Wealth LLC bought a new position in Astrazeneca during the 1st quarter valued at about $252,000. Collaborative Fund Advisors LLC acquired a new position in Astrazeneca in the first quarter valued at about $294,000. Abel Hall LLC grew its stake in Astrazeneca by 3.9% during the first quarter. Abel Hall LLC now owns 6,671 shares of the company’s stock worth $1,316,000 after buying an additional 253 shares during the last quarter. Finally, DGS Capital Management LLC acquired a new stake in shares of Astrazeneca during the first quarter worth approximately $252,000. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AZN. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a research report on Wednesday, July 1st. Weiss Ratings lowered Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 18th. Bank of America reissued a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Finally, JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a report on Tuesday, June 30th. Fourteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca Price Performance

Shares of NYSE AZN opened at $192.53 on Tuesday. The business’s 50 day moving average price is $183.97 and its two-hundred day moving average price is $188.38. The company has a market cap of $298.59 billion, a PE ratio of 28.91, a price-to-earnings-growth ratio of 1.58 and a beta of 0.24. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a twelve month low of $137.23 and a twelve month high of $212.71.

Astrazeneca (NYSE:AZN) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.52 by $0.06. The company had revenue of $15.29 billion during the quarter, compared to analysts’ expectations of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, analysts predict that Astrazeneca Plc will post 10.28 EPS for the current year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.